Novo Nordisk

Phone: +355 4 225 3522

Fax: +355 4 2253 554

E-mail: infoal@novonordisk.com

Web: https://www.novonordisk.al

Type	Aktieselskab
Traded as	Nasdaq Copenhagen: NOVO B NYSE: NVO
Industry	Pharmaceuticals, Health care
Founded	December 21, 1923 (1923-12-21)
Headquarters	Novo Allé, DK-2880, Bagsværd, Denmark
Key people	Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO)
Products	Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda
Revenue	140.8 billion kr. (2021)
Operating income	58.64 billion kr. (2021)
Net income	47.76 billion kr. (2021)
Total assets	194.5 billion kr. (2021)
Total equity	70.75 billion kr. (2021)
Number of employees	48,478 (end 2021)
Website	novonordisk.com

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 43,000 people in 80 offices around the world, and market our products in 170 countries.

For detailed contact information visit location pages below.